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A novel lateral ﬂow assay based on GoldMag
nanoparticles and its clinical applications for
genotyping ofMTHFR C677T polymorphisms
Wenli Hui,†a,b Sinong Zhang,†a Chao Zhang,a Yinsheng Wan,*c Juanli Zhu,b
Gang Zhao,d Songdi Wu,e Dujuan Xi,b Qinlu Zhang,b Ningning Lib and Yali Cui*a,b
Current techniques for single nucleotide polymorphism (SNP) detection require tedious experimental
procedures and expensive and sophisticated instruments. In this study, a visual genotyping method has
been successfully established via combining ARMS-PCR with gold magnetic nanoparticle (GoldMag)-
based lateral ﬂow assay (LFA) and applied to the genotyping of methylenetetrahydrofolate reductase
(MTHFR) C677T. C677T substitution of the gene MTHFR leads to an increased risk of diseases. The geno-
typing result is easily achievable by visual observation within 5 minutes after loading of the PCR products
onto the LFA device. The system is able to accurately assess a broad detection range of initial starting
genomic DNA amounts from 5 ng to 1200 ng per test sample. The limit of detection reaches 5 ng. Fur-
thermore, our PCR-LFA system was applied to clinical trials for screening 1721 individuals for the C677T
genotypes. The concordance rate of the genotyping results detected by PCR-LFA was up to 99.6% when
compared with the sequencing results. Collectively, our PCR-LFA has been proven to be rapid, accurate,
sensitive, and inexpensive. This new method is highly applicable for C677T SNP screening in laboratories
and clinical practices. More promisingly, it could also be extended to the detection of SNPs of other
genes.
Introduction
In recent years, detection of single nucleotide polymorphisms
(SNPs) has attracted a great deal of attention because of its
various applications in the diagnosis and treatment of genetic
diseases and use of medicines.1,2 With the development of the
next-generation sequencing (NGS) technology, it is widely used
in the sequencing of human genomes to look for disease sus-
ceptibility genes.3 With its accuracy, sequencing is always
regarded as a golden standard for nucleic acid analysis, but as
per the scale of investigation and the subsequent massive data
analysis, sequencing is more suitable for discovery of novel
SNPs4–6 than direct detection of specifically known SNPs.
Other technologies including DNA microarrays,7–9 real-time
polymerase chain reaction (RT-PCR),10,11 high resolution
melting (HRM),12 MassARRAY,13,14 the multiplex PCR-RFLP
method15 and isothermal DNA amplification16,17 also oﬀer
sensitive tools to detect SNPs. However, these techniques
require tedious experimental procedures and expensive and
sophisticated instruments that may not be available in many
laboratories. Therefore, an easy-to-operate and aﬀordable on-
site technique for genotyping with high eﬃciency has become
indispensable and urgently needed.
There is a growing interest in the development of nano-
particle-based DNA detection methods, some of which have
been successfully applied in clinical settings.18–22 Nano-
particle-associated lateral flow assay (LFA) for nucleic acid ana-
lysis, as a simple and rapid method, enables visual detection
of the target DNA, and perhaps more importantly, skips compli-
cated steps including pipetting, incubation, washing, and data
analysis.23,24 Mao et al. reported a nucleic acid biosensor based
on the oligonucleotide functionalized Au-NPs and LFA device.25
Kalogianni et al. presented lateral flow tests exploiting carbon
nanoparticles as reporters.26 In these reports, LFA test strips rely
on the hybridization reaction and are more suitable for detec-
tion of the target DNA sequence rather than SNPs.
Gold magnetic nanoparticles are novel composite particles
that integrate the superparamagnetism of Fe3O4 nanoparticles
and the surface chemistry of the Au component. The diﬀerent
structures with core/shell, dumbbell-like and flower-shape
of these nanoparticles have been reported.27–29 Herein, the†These authors contributed equally to this study and share first authorship.
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Fe3O4/Au/Fe3O4 configuration (nanoflowers) with 38 nm dia-
meter was synthesized30 and used as a carrier to set up a
device for SNP detection. Compared to other matrix nano-
particles, our patented PAA (poly-acrylic acid) modification of
GoldMag nanoparticles ensures the significantly elevated
stableness and compatibility of the particles for biological
interactions. Our nanoparticle based lateral-flow immunoassay
was also previously reported to rapidly, specifically, and accu-
rately analyze the TP antibody at the laboratory and clinical
level.31
Using MTHFR C677T genotyping as a model, we have deve-
loped a sensitive, specific, rapid, and cost-eﬀective method for
SNP detection via integrating the amplification refractory
mutation system (ARMS)-PCR with GoldMag-based lateral flow
assay (LFA). C677T is the most common SNP on methyl-
enetetrahydrofolate reductase, which is a key enzyme in folate
metabolism.32 C > T substitution results in a reduced activity
of this thermo-labile enzyme33 and causes not only folate
metabolic disorders but also accumulation of homocysteine
(Hcy). It has been reported that C677T polymorphism is
associated with a high risk of diseases34–39 such as cancer,
neurological disorders, cardiovascular diseases, and pregnancy
complications. Detection of MTHFR C677T may help predict
risk for diseases and guide the folate supplement to prevent




PAA (poly-acrylic acid) modified gold magnetic nanoparticles
(PGMNs) and lateral flow strips were from Xi’an GoldMag
Nanobiotech Co., Ltd (Xi’an, Shaanxi, PRC). Water (18.2
MΩ cm) used for all work in this report was purified by using
a Barnstead Nanopure Water system. All chemicals were of
analytical grade and purchased from reputable vendors. Buﬀer
was prepared according to standard laboratory procedures.
Anti-digoxin antibody was purchased from Meridian Life
Science, Inc. (Saco, ME, USA). Streptavidin was obtained from
Promega Biotech Inc. (Madison, WI, USA). Goat anti-mouse
IgG was from Joey Bioscience Inc. (Shanghai, PRC). HotMaster
Taq DNA polymerase and 10× buﬀer and 1× TE both were pur-
chased from TIANGEN (Beijing, PRC). dNTPs and uracil-DNA
glycosylase (UDG) were obtained from Shinegene (Shanghai,
PRC). MgCl2 (25 mM) was purchased from Thermo Scientific
(Shanghai, PRC). All oligonucleotides used in this work were
synthesized by Invitrogen (Shanghai, PRC). The commercial
genotyping kits (PCR-microarray) were from Baio technology
(Shanghai, PRC).
DNA extraction
DNA was extracted from 200 μL of blood samples using a
whole blood genomic DNA isolation kit from Xi’an GoldMag
Nanobiotech Co., Ltd (Xi’an, Shaanxi, PRC) according to the
manufacturer’s instructions. Briefly, 40 µL proteinase K,
200 µL of whole blood and 400 µL of lysis buﬀer were added
into a microfuge tube. The samples were then mixed well by
pipetting and incubated at 56 °C for 20 min. Then 100 µL of
GoldMag® particles and 400 µL of binding buﬀer were added
to the tube which was incubated at room temperature for
5 min. The tube was then placed on the magnetic separator for
2 min to magnetically separate and discard the supernatant.
The GoldMag®–DNA complexes were washed with 600 µL of
washing buﬀer-1 and 800 µL of wash buﬀer-2. 200 µL of
elution buﬀer was added to the tube and the mixture was
incubated at 56 °C in a water bath for 5 min. The tube was
put back on the magnetic separator for 3 min until the
supernatant was clear. The supernatant (DNA solution) was
transferred to another tube and ready to use.
PCR amplification
According to the principle of ARMS-PCR,43,44 the reverse
primer was designed as the common primer, and the forward
primers are allele specific primers since the nucleotide at their
3′ terminus corresponds to the SNP site. To detect the geno-
type of each sample, two complementary reactions (M tube
and WT tube) were run separately using the same DNA tem-
plate. Each PCR reaction volume was 50 μL containing 10×
PCR buﬀer (10 mM Tris HCl, 50 mM KCl), 0.2 mM of each
dNTP (dATP, dCTP, dGTP, dUTP), 3 mM of MgCl2, 0.5 U of
Hotmaster Taq DNA polymerase, 0.5 U of UDG polymerase, 50
nM reverse primer, and 3 μL genomic DNA with the concen-
trations of 10–400 ng μL−1. 50 nM of the forward (M) primer in
the M tube and the forward (WT) primer in the WT tube were
used separately. The primer sequences: forward (M) primer
5′-AGAAGGTGTCTGCGGGATT-3′; forward (WT) primer
5′-GAGAAGGTGTCTGCGGGATC-3′; reverse primer 5′-GAAA-
GATCCCGGGGACGATG-3′. The ABI PCR thermal cycler Dice
was used for the amplification. PCR was commenced with two
initial denaturation steps at 50 °C for 2 min and 95 °C for
5 min, followed by 26 cycles of denaturation at 94 °C for 30 s,
annealing at 60 °C for 30 s, and extension at 65 °C for 1 min.
The final extension step was at 65 °C for 10 min.
Conjugation of PGMNs with anti-digoxin antibody
1 mg of PAA–GMNs was equilibrated in 600 μL of phosphate
buﬀer (1 × PB, pH 7.2) and activated by EDC, anti-digoxin anti-
body was then added to the particles. This mixture was shaken
at 180 rpm for 1 h at 22 °C. After 1 h of incubation, the anti-
digoxin antibody functionalized PAA–GMN conjugates were
magnetically separated and then suspended in a PB suspension
buﬀer (1 × PB, pH 7.2, containing 1% BSA) at 2–8 °C until use.
LFA device
Via a BioJet dispenser (HM3010, BioDot Inc.), streptavidin and
goat anti-mouse IgG were pre-immobilized respectively in a
defined test line (T-line) and a control line (C-line) on a porous
nitrocellulose membrane. Then, the probe solution containing
PGMNs with an anti-digoxin antibody was dispensed on the
conjugate pad of LFA strips. These strips were placed in a card
box and stored in a sealed aluminum foil bag with desiccant
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silica gel at room temperature. The strips remain stable for
12 months.
Evaluation of C677T genotypes via LFA
After PCR amplification, the whole reaction volume (50 μL) in
two tubes were loaded on the sample pads of the LFA strips
respectively and the results were analysed. The reference DNA
samples with CC, CT and TT genotypes confirmed by sequen-
cing were used to validate the method. In order to ensure the
specificity of the assay, an additional mismatch at the penulti-
mate nucleotide of the 3′ terminus was introduced45 in the
process of primer design. The sensitivity was evaluated by
varying the concentration of DNA samples.
Clinical application and statistical analysis
1721 human whole blood samples were obtained from six hos-
pitals including 504 cases from Xiangya Hospital Central-
South University (Changsha, PRC), 313 cases from Shaanxi
Provincial People’s Hospital (Xi’an, PRC), 200 cases from
Hunan Provincial People’s Hospital (Changsha, PRC), 175
cases from Peking Union Medical College Hospital (Beijing,
PRC), 341 cases from Beijing Tiantan Hospital (Beijing, PRC)
and 188 cases from NanFang Hospital, Southern Medical Uni-
versity (Guangzhou, PRC). Appropriate ethical and governance
permission was obtained from the local authorities prior to
blood sample collection.
The genomic DNA samples extracted from whole blood
were tested in a double-blind trial. The genotype of each
sample was analysed by PCR-GoldMag based-LFA and com-
pared with the results detected by the commercial genotyping
kit (PCR-DNA microarray) or DNA sequencing. Samples dis-
playing inconsistent results with the commercial kit were re-
tested via BGI’s sequencing as the third party test. Based on
the statistics data, the coincidence rate of three genotypes and
total agreements were calculated to evaluate the accuracy of
our method.
Results and discussion
Principles of PCR-lateral flow assay
To detect polymorphism of MTHFR C677T, we established the
PCR-LFA method, which technically combines ARMS-PCR with
LFA.
The principle of PCR-LFA is schematically illustrated in
Fig. 1. With two sets of allele-specific primers (corresponding
to the wild type sequence and mutation sequence), the
ARMS-PCR technique is used to amplify target fragments
in two tubes (Fig. 1A). For one particular sample, an equal
amount of genomic DNA was added to the above two separate
PCR tubes, one as the M tube with the forward (M) primer to
detect the “T” allele and the other as the WT tube with the
forward (WT) primer to detect the “C” allele. Forward (M and
WT) and reverse (common) primers are 5′ end-labelled with
digoxin and biotin, respectively. The PCR target fragments are
synthesized while the 3′-end of the primer is complementary
with the template (Fig. 1B).
A LFA device is composed of five parts: a sample pad, a con-
jugate pad, a strip of nitrocellulose membrane, an absorbent
pad, and a plastic cushion. After PCR amplification, PCR pro-
ducts of two tubes are loaded onto the sample pads of two LFA
strips separately. PCR target fragments, if any, are complexed
with the pre-fabricated PGMN–anti-digoxin antibody conju-
gates on the adjacent conjugate pad. The subsequent DNA–
PGMN–anti-digoxin antibody conjugates migrate across the
membrane until being captured by pre-immobilized strepta-
vidin on the test line (T line) with a result of a red band. The
colour development on the T line can thus suggest whether
there are target fragments in the PCR reactions. The excessive
amount of PGMN–anti-digoxin antibody conjugates is
captured by using goat anti-mouse IgG on the control line
(C line), indicating the eﬃcacy of the system (Fig. 1C).
A final genotyping result of a sample is a combinational
visual presentation as per the colour development on the T
lines of both strips (Fig. 1D). For the homozygous sample (677
TT), a distinct red band is observable on the T line of the strip
used only for the M tube but not for the WT tube. In contrast,
for the wild-type sample (677 CC), the red band shows exclu-
sively on the strip receiving the WT tube but not the M tube.
However, when red bands with similar intensities are present
on the T lines of both strips, it indicates a heterozygous
sample (677 CT).
The result by agarose gel electrophoresis for MTHFR C677T
genotyping shows that the fragment length for the amplicon is
141 bp (Fig. 1E). 26 cycles of PCR amplification suﬃce our LFA
detection. However, electrophoresis requires at least 32 cycles
followed by a series of time-consuming steps. In addition, the
C677T genotyping results detected by sequencing are displayed
as a comparison (Fig. 1F).
PCR-LFA combines simple, cost-eﬀective ARMS-PCR with
quick LFA. Our PCR-LFA is faster than existing methods. After
ARMS-PCR, the lateral flow device is used to detect PCR pro-
ducts. It takes only 5 min to obtain the detection results
without the need for expensive or high-end instruments. The
whole process for the genotyping of MTHFR C677T could be
analysed within two hours. Our assay skipped or minimized
various experimental steps, such as pipetting, gel casting/
purchasing, DNA separation, and UV visualization. We also
proved that our method is more convenient than hybrid based
microarray methods or other reported nucleic acid lateral flow
assays.46,47 Therefore, this method can be used in the labora-
tories of all levels of hospitals and medical institutions,
especially for laboratories with limited resources.
Optimization of ARMS-PCR and LFA system for MTHFR
genotyping
To improve the sensitivity and specificity of our method for
MTHFR C677T genotyping, we systematically optimized the
ARMS-PCR procedure, LFA strip preparation and detecting
conditions.
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Fig. 1 Schematic diagram of the PCR-lateral ﬂow assay (LFA) system. (A) Detecting one sample requires two tubes: M and WT tubes. (B) The
process of ARMS-PCR. The PCR target fragment is synthesized while the 3’-end of the primer is complementary with the template. (C) After PCR
ampliﬁcation, PCR products are loaded on the sample pad of LFA strips. The target fragments carrying the labels of biotin and digoxin are able to
conjugate with the PGMN–anti-digoxin antibody complex and thus forms a further complex which is captured by streptavidin on the test line with
an appearance of a red band. The excessive PGMN–anti-digoxin antibody complex can be precipitated by the goat anti-mouse IgG on the control
line. (D) The genotyping result of homozygous, heterozygous and wild type sample by PCR-LFA. M = M tube. WT = WT tube. (E) The agarose gel
electrophoresis results showing the detection of MTHFR C677T by ARMS-PCR. M = M tube. WT = WT tube. (F) The sequencing results for MTHFR
C677T genotyping.
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ARMS-PCR. To obtain the optimal performance, we care-
fully considered the design of primers and the concentration
of primers, the use of dUTP and uracil–DNA glycosylase, and
the PCR cycles. In order to ensure the specificity, an additional
mismatch at the penultimate nucleotide of the 3′ terminus of
allele specific forward primers was introduced based on the
principle of ARMS-PCR.45 To determine the optimal concen-
tration of the primers, diﬀerent concentrations (200, 100, 50,
25 nM) of each primer were used into the ARMS-PCR mix. The
results showed that 50 nM primers were optimal for MTHFR
C677T genotyping (Fig. 2A). Uracil–DNA glycosylase (UDG) is
an enzyme utilized in our method to eliminate carryover PCR
products containing dUTP. A simple digestion step (50 °C,
2 min) was used prior to the subsequent PCR reaction. PCR
products from previous PCR operation (i.e. the possible con-
taminant) and the genomic DNA need to be tested were
together added into the tubes as the template. Without UDG,
the PCR products displayed false positive results, as shown in
Fig. 2B, all genotyping results were heterozygous including the
negative control. The use of UDG ensures amplification of the
desired genomic DNA (Fig. 2C). Therefore, in a new reaction,
residual amplicons from previous PCR will be digested, only
the desired DNA templates will be amplified and remain
unaﬀected. We also tested PCR cycles (e.g. 25, 26, 27, 28, 29
cycles), considering that may aﬀect the sensitivity and speci-
ficity of the method. The data showed that the optimal cycle
number was 26 in our system (Fig. 2D).
Lateral flow assay device. We optimized the amount of anti-
digoxin antibody conjugated with PGMNs. 1 mg of PAA-
modified GoldMag nanoparticles was conjugated with various
concentrations of digoxin antibody (Fig. 2E). Based on the
data, 150 μg of digoxin antibodies per mg of PGMNs as the
optimum oﬀered a cost-eﬀective readout signal. Other para-
meters, including the pH of the buﬀer, the type of nitro-
cellulose membrane, and the lateral flow time, were also
investigated and optimized (data not shown).
Validation of PCR-LFA. Under optimal experimental con-
ditions, we further examined the performance of the PCR-LFA
with diﬀerent concentrations of genomic DNA. We also evalu-
ated the sensitivity and specificity of PCR-LFA. A gradient of
template assessment was prepared (e.g. 1, 5, 10, 30, 50, 100,
300, 500, 800, 1000, 1200 ng of genomic DNA) for PCR reac-
tions of 26 cycles. The concomitant PCR amplicons were
detected by using the LFA strips (Fig. 3). When the dosage of
the initial template was in the range of 5–1200 ng, the PCR
amplification eﬃciency significantly improved as the dose of
the template increased. Even when the dose was up to 1200
ng, the specificity of the test remained high with no false-posi-
tive result. Normally, the concentration of genomic DNA
extracted from human blood samples is in the range of 10–400
ng μL−1. Therefore, in this method, the DNA dilution process
can be omitted.
Under our optimized conditions and signal amplifications,
the detection limit of PCR-LFA can reach 5 ng of the starting
DNA sample, which is comparable to the commercial kit
(PCR-DNA microassay). Our optimized method also exhibits
high specificity with no false positive result. Higher sensitivity
but no false positive readout makes this method unique and
Fig. 2 Optimization of the detection system. M = M tube. WT = WT tube. (A) The concentration of primers. 50 nM primer was proved to be optimal.
(B) Addition of the PCR template comprising the genuine genomic DNA and the carryover PCR products from previous PCR reaction into the
ARMS-PCR mix. Without UDG, the results were aﬀected by PCR products. (C) The eﬀect of UDG that was used to prevent contamination. The results
were not aﬀected from the carryover PCR products. (D) The cycles of PCR ampliﬁcation. 26 cycles were the optimal. (E) The test of the amount of
anti-digoxin antibody conjugated with PGMNs with 150 μg of anti-digoxin as the optimum.
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more applicable. Furthermore, in the PCR part of our assay, we
methodologically introduced mismatches at the 3rd nucleotide
from the 3′-ends of the primers, and found that this modifi-
cation has a crucial impact on the specificity of our method, as
some allele-specific primers completely lost specificity upon
removal of the mismatch.48 This would favour clinical appli-
cations that demand unconditional specificity and accuracy, in
addition to the speed of the assay. Technically, the capacity of
antibody conjugation upon nanoparticles is critical for the
assay. In general, the conjugating capacity of other kinds of
nanoparticles with antibodies is diﬃcult to reach 50 μg mg−1.
However, due to the novel GoldMag nanoparticle structure
(nanoflowers),30 in our method, the conjugated antibodies can
achieve more than 100 μg mg−1. This ensures the sensitivity
and stability of our established PCR-lateral flow assay.30,31
Clinical applications
To further validate and extend our PCR-LFA method for the
SNP of MTHFR, we carried out a double-blind trial with 1721
clinical samples. Each sample was tested by using our
PCR-LFA strips and the commercial genotyping kit (PCR-DNA
microarray) or DNA sequencing as a comparison.
1192 samples from Xiangya Hospital Central-South Univer-
sity, Shaanxi Provincial People’s Hospital, Hunan Province
People’s Hospital and Peking Union Medical College Hospital
were tested by using the commercial genotyping kit (PCR-DNA
microarray). The other 529 samples from Beijing Tiantan
Hospital and NanFang Hospital, Southern Medical University
were tested by DNA sequencing. The genotype-specific con-
cordance among the three methods is shown in Table 1.
For the 1192 samples, the statistical data showed that there
were 33 discrepant samples and they were addressed via BGI’s
sequencing as a third party. DNA sequencing analysis revealed
that the results of 26 samples were identical to the PCR-LFA
method, 7 samples were agreeable with the commercial kit
(PCR-DNA microarray). The data indicate that compared to the
commercial kit, PCR-LFA is able to well serve as a more accu-
rate assessing tool. The final consistency rates for CC, CT, TT
types were 99%, 100%, and 98.78%, respectively. For the 529
samples, the results of PCR-LFA were in good agreement with
the sequencing results, and the consistency rate was 100%.
These results clearly demonstrate that our new method is
comparable to the DNA sequencing in MTHFR C677T
genotyping.
Testing for MTHFR 677 genotypes of 1721 clinical samples
reveals that PCR-LFA outperforms the commercially available
kit at the level of accuracy, and is also able to match the
sequencing method, by obtaining the concordance rate of
genotyping up to 99.6%. For the remaining 7 discrepant
samples, we used PCR-LFA to re-test. The results were in
accordance with the sequencing data (re-test results were not
counted in clinical trials). Compared with the commercial kit
and sequencing results, the consistency rates for CC, CT and
TT types were 99.2%, 100%, and 99.2%, respectively. The total
consistency rate was 99.6%.
In addition, we analysed the genotype and allele frequency
of 1721 cases (Fig. 4). The genotype frequencies of MTHFR 677
CC, CT, TT types were 28.82% (492 cases), 49.22% (851 cases)
and 21.96% (378 cases) (Fig. 4A). The allele frequency for the C
allele was 53.43% and the T allele was 46.57% (Fig. 4B). The
Fig. 3 LFA strips after analysis of homozygous DNA (TT), heterozygous DNA (CT), wild-type DNA (CC) based on ARMS-PCR. M = M tube. WT = WT
tube. Using template dosage gradient to verify the sensitivity and speciﬁcity, in the dose range of 5–1200 ng, the detection limit can reach 5 ng. The
method exhibits high speciﬁcity with no false positive result.
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sample size data for genotyping of six hospitals are shown in
Fig. 4C.
Conclusions
In this report, we presented a PCR-lateral flow assay for detec-
tion of SNP from genomic DNA samples, using our patented
gold magnetic nanoparticles (GoldMag) as a carrier. This is
the first report that a system combined the amplification
refractory mutation system (ARMS)-PCR with GoldMag-based
lateral flow assay (LFA) for genotyping. Our data have demon-
strated that this assay is highly applicable for detection of SNP
of MTHFR C677T in clinical practice due to its unparalleled
advantages, such as superior sensitivity and specificity, low
cost, easy operation, simple procedure, and no need for
expensive instruments. Since detection for this SNP has sig-
nificant clinical values, in our laboratory this method has
already been extended to SNP detection of other genes related
to folic acid metabolism. It is envisaged that our newly estab-
lished PCR-LFA could be quickly adapted for the detection of
other SNPs of genes that are associated with disease risk, drug
metabolism, or drug reaction.
Acknowledgements
This study was supported by the Project of National Great New
Drug Research and Development China (No. 2012ZX09506001-





Total Agreement%CC CT TT
Discrepant
samples CC CT TT
Discrepant
samples
Hospitala,b,c,d (PCR-LFA) 1192 CC 387 8 3 11 11 0 0 0 398 99%
CT 14 556 5 19 4 12 3 7 575 100%
TT 1 2 216 3 0 0 3 0 219 98.78%
Hospitale, f (PCR-LFA) 529 CC — — — — 94 0 0 0 94 100%
CT — — — — 0 279 0 0 279 100%
TT — — — — 0 0 156 0 156 100%
Total (PCR-LFA) 1721 CC 398 0 0 0 94 0 0 0 492 99.2%
CT 4 568 3 7 0 279 0 0 854 100%
TT 0 0 219 0 0 0 156 0 375 99.2%
a Xiangya Hospital Central-South University. bHunan Provincial People’s Hospital. c Shaanxi Provincial People’s Hospital. d Peking Union Medical
College Hospital. e Beijing Tiantan Hospital. fNanFang Hospital, Southern Medical University.
Fig. 4 Pie chart for the genotype and allele frequency of MTHFR C677T with 1721 cases. (A) Genotype frequencies of MTHFR C677T. (B) Allele fre-
quencies of T and C alleles. (C) The sample size data for genotyping of six hospitals. (a) Xiangya Hospital Central-South University. (b) Hunan Provin-
cial People’s Hospital. (c) Shaanxi Provincial People’s Hospital. (d) Peking Union Medical College Hospital. (e) Beijing Tiantan Hospital. (f ) NanFang
Hospital, Southern Medical University.
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